Charite Universitaetsmedizin Berlin - Campus Charite Mitte
Charite Universitaetsmedizin Berlin - Campus Charite Mitte
Berlin, Germany6 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of INCA036978 in Participants With Myeloproliferative Neoplasms | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, essential thrombocythemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, neoplasm, primary myelofibrosis, thrombocytosis disease | Recruiting | Phase 1 | 2026-10-09 | NCT07441694 | |
| A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, nephritis, urinary system disorder | Active, not recruiting | Phase 3 | 2026-10-05 | NCT05797610 | |
| A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Active, not recruiting | Phase 2 | 2026-09-28 | NCT05242484 | |
| A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Active, not recruiting | Phase 2 | 2026-09-28 | NCT05242471 | |
| A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) | NonSegmental Vitiligo | Active, not recruiting | Phase 3 | 2026-03-31 | NCT06113471 | |
| Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, brain disorder, central nervous system cancer, central nervous system disorder, melanocytic neoplasm, melanoma, neoplasm, nervous system disorder, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Active, not recruiting | Phase 3 | 2025-09-24 | NCT04674683 |